2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes

Salt Lake City, UT US
October 7, 2022 to October 8, 2022

The 2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of implications of actionable molecular alterations across common malignancies.

Expert faculty will discuss and analyze the latest scientific findings and practice-changing advances in precision oncology, including the key abstracts relevant to precision oncology presented at the 2022 ASCO Annual Meeting in June 2022.

This conference will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:

  • Integrating different platforms available for testing of actionable molecular alterations for identification of targeted therapy options.
  • Current and evolving paradigms in precision oncology approach for management of common malignancies.
  • Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.

Call For abstract

Abstract submission deadline: July 31, 2022

Submit to one of the following categories:

  1. Basic science research
  2. Clinical research
  3. Quality-of-care research
  4. Outcomes research
  5. Case reports and case-series

Abstract decisions will be emailed to the first author by August 15, 2022

Click here to submit abstracts

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

 

Learning Objectives

Upon successful completion of this educational activity on precision oncology, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand appropriate timing of testing to detect these abnormalities.
  • Interpret results of next generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for selection of targeted therapies.
  • Plan optimal molecular-targeted treatment strategies for treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in clinical investigation for cancer patients.
Course summary
Available credit: 
  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.
Course opens: 
04/27/2022
Course expires: 
10/08/2022
Event starts: 
10/07/2022 - 7:00am PDT
Event ends: 
10/08/2022 - 4:00pm PDT
Cost:
$350.00

All times below are listed in Mountain Standard Time. 

Friday, October 7th, 2022

 

3:00 PM to 3:45 PM          Registration


3:45 PM to 4:00 PM          Welcome note from the conference chair - Neeraj Agarwal, MD


4:00 PM to 6:00 PM          Session 1: Methods in Precision Oncology 

Moderator: Christos Vaklavas, MD

4:00 PM to 4:20 PM           Next generation sequencing for identification of molecular targets  - James Ford, MD

4:25 PM to 4:45 PM           Beyond sequencing – methods in identifying tumor biomarkers for targeted therapies - Vivek Subbiah, MD

4:50 PM to 5:10 PM           Germline genetic testing for cancer prevention and treatment - Siddhartha Yadav, MD

5:15 PM to 5:35 PM           Clinical utility of circulating tumor DNA in cancer treatment - Manish Kohli, MD

5:35 PM to 6:00 PM           Q and A/Panel discussion


6:00 PM to 8:00 PM          Dinner & Abstract Session


Saturday, October 8th, 2022

7:00 AM to 7:30 AM          Breakfast and registration


7:30 AM to 8:45 AM          Session 2: Precision oncology in breast cancer

Moderator: Paolo Tarantino, MD                  

7:30 AM to 7:45 AM          Precision oncology in metastatic breast cancer - Mark Pegram, MD

7:45 AM to 8:00 AM          Non-metastatic breast cancer - Christos Vaklavas, MD

8:00 AM to 8:45 AM          Panel discussion


8:45 AM to 10:00 AM        Session 3: Precision Oncology in Lung Cancer

Moderator :                     

8:45 AM to 9:00 AM          Metastatic lung cancer - Katie Kerrigan, MO      

9:00 AM to 9:15 AM          Adjuvant treatment of lung cancer - Aaron Mansfield, MD

9:15 AM to 10:00 AM        Panel discussion


10:00 AM – 10:30 AM       Break


10:30 AM to 11:15 AM      Session 4: Precision Oncology in GI Malignancies

Moderator: Chandrikha Chandrasekhara, MBBS                      

10:30 AM to 10:45 AM      Precision Oncology in Colon cancer - Stacey Cohen, MD

10:45 AM to 11:00 AM      Hepatobiliary and pancreatic malignancies - Chris Nevala-Plagemann, MD

11:00 AM to 11:15 AM      Panel based discussion


11:15 AM – 12:00 PM Session 5: Precision oncology in gynecologic malignancies    

11:20 - 11: 35 Key concepts on precision in gynecological malignancies - Theresa Werner, MD

11:35 - 12:00: Case discussion


12:00 PM to 1:00 PM        Lunch


1:00 PM to 2:15 PM          Session 5: Precision oncology in GU malignancies

Moderator: Benjamin Maughan, MD                        

1:00 PM to 1:15 PM           Metastatic prostate cancer - Neeraj Agarwal, MD

1:15 PM to 1:30 PM           Non-metastatic prostate cancer - Benjamin Maughan, MD

1:30 PM to 2:15 PM           Q & A


2:15 PM – 2:30 PM            Break


2:30 PM to 3:30 PM          Session 6: Precision oncology in hematological malignancies

Moderator:

2:30 PM to 2:45 PM           Precision oncology in acute leukemias - Tibor Kovacsovics, MD

2:45 PM to 3:00 PM           Precision oncology in myeloma and lymphomas

3:00 PM to 3:30 PM           Panel discussion


3:30 PM to 4:45 PM          Session 7: Implementation science in precision oncology

Moderator:

3:30 PM to 3:45 PM           Disparities in precision oncology and improving access to evidence-based testing for targeted therapies - Jack West, MD

3:45 PM to 4:00 PM           Implementing precision genomics in busy clinical practice – how to?

4:00 PM to 4:15 PM           Patient perspective in precision oncology

4:15 PM to 4:45 PM           Panel discussion


4:45 PM to 5:00 PM          Concluding remarks - Neeraj Agarwal, MD

 

Hilton Salt Lake City Center
255 S W Temple
Salt Lake City, UT 84101
United States

 

 

Moderator(s)

Chandrikha Chandrasekharan, MBBS

has no relevant financial relationships to disclose at this time.

Paolo Tarantino, MD

has a financial relationship (Professional Services) with AstraZeneca;.
Speaker(s)

James Ford, MD, FASCO

has no relevant financial relationships to disclose at this time.

Manish Kohli

has a financial relationship (Independent contractor) with Bristol Meyer Squibb/Celgene;.
has a financial relationship (Independent contractor) with Genapsys Inc.;.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Peloton Therapeutis;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer Oncology;.
has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Astellas;.

Christopher Nevala-Plagemann, MD, MSCI

has no relevant financial relationships to disclose at this time.

Mark Pegram, MD

has no relevant financial relationships to disclose at this time.

Vivek Subbiah, MD

has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with LOXO/ Eli Lilly;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Relay Therapeutics;.

Christos Vaklavas, M.D., Associate Professor

has no relevant financial relationships to disclose at this time.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Takeda;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.

Available Credit

  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

Price

Cost:
$350.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $350

Non-physician HCP (non-industry) - $250

Industry representatives - $850

Fellow or resident - $150

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Cancellation Policy

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.